1Durham PL,Vause CV.Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine[J].CNS Drugs,2010,24(7):539-548.
2Charbit AR,Akerman S,Goadsby PJ.Comparison of the effects of central and peripheral dopamine receptor activation on evoked firing in the trigeminocervical complex[J].J Pharmacol Exp Ther,2009,331(2):752-763.
3Jansen-Olesen,Zhou HI,Zinck T,et al.Expression of inducible nitric oxide synthase in trigeminal ganglion cells during culture[J].Basic clin phannacol Toxico1,2005,97(6):355-336.
4Filica V,Vladicb A,Stefulj J,et al.Monoamine oxidases A and B gene polymorphisms in migraine patients[J].J Neurol Sci,2005,228(2):149-153.
5Kowa H,Fusayasu E,I jiri T,et al.Association of the insertion deletion polymorphism of the angiotensin-convertingenzyme gene in patients of migraine with aura[J].Neuorsci Lett,2005,374(2):129-131.
6Vanmolkol KR,Terwindt GM,Frants RR,et a1.A gene for a new monogenic neurovascular migraine syndrome:a next step in unravelling molecular pathways for migraine[J].Cephalalgia,2008,28(5):471-473.
7Van den Maagdenberg AM,Haan J,Terwindt GM,et al.Migraine:gene mutation and functional consequences[J].Curr Opin Neurol,2007,20(3):299-305.
8Ahmed HE,White PF,Craig WF,et al.Use of percutaneous elect rical nerve stimulation (PENS) in the short-term management of headache[J].Headache,2000,40(6):311.
9Suzuki K,Iizuka T,Sakai F.Botulinum toxin type A for migraine prophylaxis in the Japanese population:an open-label prospective trial[J].Intern Med,2007,46(13):959-963.
10Aurom SK,Gawel M,Brandes JL,et a1.Botulinure toxin type A prophylactic treatment of episodic migraine:a randomized,double-blind,placebo-controlled exploratory study[J].Headache,2007,47(4):486-499.
